Abstract
The gut microbiota has emerged as a key factor in the pathogenesis of intestinal viruses, including enteroviruses, noroviruses and rotaviruses (RV), where stimulatory and inhibitory effects on infectivity have been reported. With the aim of determining whether members of the microbiota interact with RV during infection, a combination of anti-RV antibody labelling, fluorescence-activated cell sorting and 16S rRNA amplicon sequencing was used to characterize the interaction between specific bacteria and RV in stool samples of children suffering diarrhea produced by G1P[8] RV. The genera Ruminococcus and Oxalobacter were identified as RV binders in stools, displaying enrichments between 4.8 to 5.4-fold compared to samples non-labelled with anti-RV antibodies. In vitro binding of the G1P[8] Wa human RV strain to two Ruminococcus gauvreauii human isolates was confirmed by fluorescence microscopy. Analysis in R. gauvreauii with antibodies directed to several histo-blood group antigens (HBGA) indicated that these bacteria express HBGA-like substances at their surfaces that can be the target for RV binding. Furthermore, in vitro infection of Wa strain in differentiated Caco-2 cells was significantly reduced by incubation with R. gauvreauii. These data, together with previous findings that had shown a negative correlation between Ruminococcus levels and antibody titers to RV in healthy individuals, suggest a pivotal interaction between this bacterial group and human RV. These results reveal likely mechanisms on how specific bacterial taxa of the intestinal microbiota could negatively affect RV infection and open new possibilities for anti-viral strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Spanish Government (Ministerio de Economia y Competitividad) grants AGL2017-84165-C2-1-R to MJY, AGL2017-84165-C2-2-R and RYC-2013-12442 to JRD. This work was also supported by Valencian Government grant IDIFEDER/2018/056. RGR is the recipient of a postdoctoral grant from the Valencian Government APOST/2017/037. CSB is the recipient of a predoctoral grant FPI from the Spanish Government RE2018-083315. SVV is the recipient of a predoctoral grant from the Valencian Government ACIF/2016/437.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted with the approval of the Ethics Committee of the Hospital (code F-CE-GEva-15; 26 March 2015), and informed written consent was obtained from patients' parents/tutors before sample collection.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The dataset supporting the conclusions of this article is available in the NCBI's Sequence Read Archive (SRA) repository, BioProject ID PRJNA676006
